Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMEISMUSCLE: Add-on IVIg in Early Myositis
NCT05832034Phase 3Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- Sep 2021
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Nanogam in idiopathic inflammatory myopathy (IIM), sponsored by University of Amsterdam. Started Sep 2021; status: active, not recruiting.
02
Drugs
Nanogam
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT05832034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832034.